Asthma | Patient Profiler | US | 2018

The U.S. asthma market has become increasingly crowded with a large number of approved therapies. Those include several LABA/ICSFDCs (i.e., GlaxoSmithKline’s Advair and Breo, AstraZeneca’s Symbicort, Merck & Co.’s Dulera, and Teva Pharmaceutical’s AirDuo and its authorized generic), numerous ICSs (e.g., GSK’s Flovent, Teva’s Qvar), a number of SABAs (e.g., Teva’s ProAir, GSK’s Ventolin), montelukast (Merck’s Singulair), Boehringer Ingelheim’s Spiriva, and biologics (Roche’s Xolair, GSK’s Nucala, Teva’s Cinqair, and AstraZeneca’s Fasenra), among others. The market is expected to become even more competitive in the next few years, with upcoming approvals of additional biological agents and triple LABA/LAMA/ICS combinations, making brand differentiation and understanding of key patient characteristics ever more critical for marketers.

Questions Answered

• What are the demographic characteristics and clinical profiles of asthma patients receiving maintenance treatment with ICSs, LABA/ICSFDCs, LAMAs, SABAs, and biologics?
• What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for asthma?
• How do patient cohorts for asthma compare in care utilization and outcomes (physician visits and other healthcare encounters)?
• What insurance type do asthma patients have?
• What are the reimbursed and out-of-pocket costs?
• What provider specialties are associated with asthma patient claims?

Product Description

Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive real-world data (RWD) repository.

Markets covered: United States

Real-World data: U.S. electronic health records and claims data

Key drugs covered: Advair, Symbicort, Dulera, Breo, AirDuo, salmeterol/fluticasone generic, Xolair, Nucala, Spiriva, Incruse, Qvar, Flovent, ProAir, Ventolin, and others

Key analysis provided:

• Patient demographics.
• Disease-Specific lab tests and values.
• Risk factors and comorbidities.
• Coprescribing and adjunct therapy prescribing for comorbid conditions.
• Insurance type and reimbursement/cost analysis.
• Utilization of care and physician and prescriber demographics.